Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 52.35% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 40.50M.
Undervalued
The company’s latest PE is -2.07, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.36M shares, decreasing 30.94% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 88.47K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.96.